<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="613">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153174</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002021</org_study_id>
    <nct_id>NCT05153174</nct_id>
  </id_info>
  <brief_title>Study of Sulphoraphane in Chronic Kidney Disease</brief_title>
  <official_title>Safety, Feasibility and Efficacy of Sulforaphane (Avmacol) in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of the compound sulforaphane that boosts the&#xD;
      activity of antioxidant genes in the body to combat oxidative stress. Oxidative stress has&#xD;
      been shown experimentally to play a role in kidney disease. This drug has been tested in&#xD;
      patients with breast cancer who have normal kidney function, but has never been tested in&#xD;
      patients with kidney disease.&#xD;
&#xD;
      In this study, the investigators will establish a safe dose for patients with chronic kidney&#xD;
      disease based on blood levels achieved in patients with normal kidney function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC 0-8h) in serum</measure>
    <time_frame>prior to initial dose on day 7 and 2, 4, and 8 hours post-dose</time_frame>
    <description>Sulforaphane drug levels will be measured in serum at 0, 2, 4, and 8 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC 0-8h) in urine</measure>
    <time_frame>prior to initial dose on day 7 and 2, 4, and 8 hours post-dose</time_frame>
    <description>Sulforaphane drug levels will be measured in urine at 0, 2, 4, and 8 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an adverse event</measure>
    <time_frame>day 7</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Kidney Disease stage3</condition>
  <condition>Chronic Kidney Disease stage4</condition>
  <arm_group>
    <arm_group_label>2 tablets of Sulforaphane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given 2 extra strength tablets per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 tablets of Sulforaphane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given 4 extra strength tablets per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 tablets of Sulforaphane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given 6 extra strength tablets per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulforaphane</intervention_name>
    <description>This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.</description>
    <arm_group_label>2 tablets of Sulforaphane</arm_group_label>
    <arm_group_label>4 tablets of Sulforaphane</arm_group_label>
    <arm_group_label>6 tablets of Sulforaphane</arm_group_label>
    <other_name>Avmacol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  eGFR ≥ 20 and &lt;60 ml/min/m2/year, and a decline in eGFR of ≥ 3 ml/min/m2/year in the&#xD;
             previous 12 months&#xD;
&#xD;
          -  Blood pressure &lt;140/90 mm Hg prior to initiation of sulphoraphane&#xD;
&#xD;
          -  stable anti-hypertensive regimen for at least one month prior to initiation of&#xD;
             sulphoraphane or successful run-in period&#xD;
&#xD;
          -  able to provide consent&#xD;
&#xD;
          -  able to swallow capsules&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  significant co-morbid conditions with life expectancy of &lt;1 year&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
&#xD;
          -  serum potassium of &gt;5.5 mEq/L at screening&#xD;
&#xD;
          -  New York Heart Association Class 3 or 4 heart failure symptoms, known EF ≤30% or&#xD;
             hospital admission for heart failure within the past 3 months&#xD;
&#xD;
          -  factors judged to limit adherence to interventions&#xD;
&#xD;
          -  current participation in another study&#xD;
&#xD;
          -  pregnancy or planning to become pregnant or currently breastfeeding&#xD;
&#xD;
          -  history of dementia&#xD;
&#xD;
          -  on anticoagulants or immunosuppression&#xD;
&#xD;
          -  under treatment for cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Allison Stewart</last_name>
    <phone>585-273-4259</phone>
    <email>allison_stewart@urmc.rochester.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Thu Le</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforaphane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared after publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

